|
|
https://mb.cision.com/Public/18595/3873928/a3d5ba21aa488d95_800x800ar.png
Post hoc analysis showed meaningful efficacy of certolizumab pegol for R=
A patients with high Rheumatoid Factor RF levels
=C2=B7 A post hoc analysis from the EXXELERATE trial shows that 65.7 percen=
t of certolizumab pegoltreated patients, and 48.3 percent of adalimumabtr=
eated patients, with rheumatoid... Lire le communiqué |
|
| |
|
| |
|
|
https://mb.cision.com/Public/18595/3873881/a9f1eccc0d70ff8d_800x800ar.png
UCB receives CHMP positive opinion for rozanolixizumab for treatment of =
adults with generalized myasthenia gravis in Europe
=C2=B7 The Committee for Medicinal Products for Human Use CHMP positive o=
pinion^1 is based on the pivotal Phase 3 MycarinG study in generalized myas=
thenia gravis gMG in adult... Lire le communiqué |
|
| |
|
| |
|
|
https://mb.cision.com/Public/18595/3871568/87f55c419e37d85a_800x800ar.png
UCB Presents New FiveYear Data on BIMZELX^=C2=AE=E2=96=BCbimekizumab =
in Ankylosing Spondylitis at ACR Convergence 2023
=C2=B7 Longterm data on bimekizumab in the treatment of adults with ankylo=
sing spondylitis showed sustained improvements for up to five years with th=
e safety profile consistent with... Lire le communiqué |
|
| |
|
| |
|
|
https://mb.cision.com/Public/18595/3870395/a4440eb2e8e4629f_800x800ar.png
UCB launches an offer to the public of 6year 5.20% fixed rate notes in =
Belgium and in Luxembourg
ADVERTISEMENT This document is an advertisement for the purposes of the P=
rospectus Regulation as defined below.
THIS ANNOUNCEMENT IS NOT INTENDED FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY,=
IN OR INTO THE... Lire le communiqué |
|
| |
|
| |
|
|
https://mb.cision.com/Public/18595/3866568/9cb442c3c4c57883_800x800ar.png
UCB presents latest data from generalized myasthenia gravis portfolio at=
2023 AANEM Annual Meeting and MGFA Scientific Session
=C2=B7 14 presentations =E2=80=93 including 3 oral sessions =E2=80=93 have =
been selected by AANEM and MGFA for inclusion within scientific programs
=C2=B7 Results presented across... Lire le communiqué |
|
| |
|
| |
|
|
https://mb.cision.com/Public/18595/3855705/989749e26adbb5f8_800x800ar.png
BIMZELX^=C2=AE Approved by the U.S. FDA for the Treatment of Adults with=
Moderate to Severe Plaque Psoriasis
=C2=B7 BIMZELX^=C2=AE bimekizumabbkzx is the first and only IL17A and I=
L17F inhibitor approved for the treatment of adults with moderate to sever=
e plaque psoriasis=C2=A0
=C2=B7 Approval is... Lire le communiqué |
|
| |
|
| |
|
|
https://mb.cision.com/Public/18595/3855610/b87e61056f6b1e26_800x800ar.png
UCB announces U.S. FDA approval of ZILBRYSQ^=C2=AE zilucoplan for the =
treatment of adults with generalized myasthenia gravis
=C2=B7 FDA approval of ZILBRYSQ^=C2=AE zilucoplan has been granted for th=
e treatment of generalized myasthenia gravis gMG in adult patients who ar=
e antiacetylcholine receptor AChR... Lire le communiqué |
|
| |
|
| |
